Eli Lilly’s Cyramza (ramucirumab) Receives FDA’s Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma
Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster Headache in Adults
Shots:
- The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC patients in the ratio (2:1) with alpha-fetoprotein (AFP) ≥ 400 ng/mL prior treated with sorafenib
- The REACH-2 study (NCT02435433) resulted in meeting its 1EPs i.e median OS (8.5mos. vs 7.3mos.), mPFS (2.8 vs 1.6mos.), ORR (4.6% vs 1.1%)
- Cyramza (ramucirumab, 8 mg/kg, q2w, IV) is a VEGFR2 antagonist and has received FDA’s approval as a monothx. or in combination with paclitaxel & docetaxel for advanced or m-gastric cancer & m-NSCLC respectively
Click here, Click here, to read full press release/ article | Ref: US FDA, Eli Lilly | Image: Bolon